Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

579 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical, Angiographic, and Procedural Correlates of Very Late Absorb Scaffold Thrombosis: Multistudy Registry Results.
Ellis SG, Gori T, Serruys PW, Nef H, Steffenino G, Brugaletta S, Munzel T, Feliz C, Schmidt G, Sabaté M, Onuma Y, van Geuns RJ, Gao RL, Menichelli M, Kereiakes DJ, Stone GW, Testa L, Kimura T, Abizaid A. Ellis SG, et al. Among authors: kereiakes dj. JACC Cardiovasc Interv. 2018 Apr 9;11(7):638-644. doi: 10.1016/j.jcin.2017.11.042. JACC Cardiovasc Interv. 2018. PMID: 29622141 Free article.
Comparison of everolimus- and paclitaxel-eluting stents in patients with acute and stable coronary syndromes: pooled results from the SPIRIT (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (A Trial of Everolimus-Eluting Stents and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice) Trials.
Planer D, Smits PC, Kereiakes DJ, Kedhi E, Fahy M, Xu K, Serruys PW, Stone GW. Planer D, et al. Among authors: kereiakes dj. JACC Cardiovasc Interv. 2011 Oct;4(10):1104-15. doi: 10.1016/j.jcin.2011.06.018. JACC Cardiovasc Interv. 2011. PMID: 22017936 Free article. Clinical Trial.
Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials.
Claessen BE, Smits PC, Kereiakes DJ, Parise H, Fahy M, Kedhi E, Serruys PW, Lansky AJ, Cristea E, Sudhir K, Sood P, Simonton CA, Stone GW. Claessen BE, et al. Among authors: kereiakes dj. JACC Cardiovasc Interv. 2011 Nov;4(11):1209-15. doi: 10.1016/j.jcin.2011.07.016. JACC Cardiovasc Interv. 2011. PMID: 22115661 Free article.
In mildly symptomatic patients, should an invasive strategy with catheterization and revascularization be routinely undertaken?: in mildly symptomatic patients, an invasive strategy with catheterization and revascularization should be routinely undertaken.
Kereiakes DJ, Stone GW. Kereiakes DJ, et al. Circ Cardiovasc Interv. 2013 Feb;6(1):107-13; discussion 113. doi: 10.1161/CIRCINTERVENTIONS.112.000112. Circ Cardiovasc Interv. 2013. PMID: 23424270 No abstract available.
Novel 3-Dimensional Vessel and Scaffold Reconstruction Methodology for the Assessment of Strut-Level Wall Shear Stress After Deployment of Bioresorbable Vascular Scaffolds From the ABSORB III Imaging Substudy.
Gogas BD, Yang B, Piccinelli M, Giddens DP, King SB 3rd, Kereiakes DJ, Ellis SG, Stone GW, Veneziani A, Samady H. Gogas BD, et al. Among authors: kereiakes dj. JACC Cardiovasc Interv. 2016 Mar 14;9(5):501-3. doi: 10.1016/j.jcin.2016.01.008. JACC Cardiovasc Interv. 2016. PMID: 26965940 Free article. No abstract available.
Efficacy and Safety of the Absorb Everolimus-Eluting Bioresorbable Scaffold for Treatment of Patients With Diabetes Mellitus: Results of the Absorb Diabetic Substudy.
Kereiakes DJ, Ellis SG, Kimura T, Abizaid A, Zhao W, Veldhof S, Vu MT, Zhang Z, Onuma Y, Chevalier B, Serruys PW, Stone GW. Kereiakes DJ, et al. JACC Cardiovasc Interv. 2017 Jan 9;10(1):42-49. doi: 10.1016/j.jcin.2016.10.019. Epub 2016 Dec 21. JACC Cardiovasc Interv. 2017. PMID: 28017311 Free article.
Economic Outcomes of Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention: 1-Year Results From the ABSORB III Trial.
Baron SJ, Lei Y, Chinnakondepalli K, Vilain K, Magnuson EA, Kereiakes DJ, Ellis SG, Stone GW, Cohen DJ; ABSORB III Investigators. Baron SJ, et al. Among authors: kereiakes dj. JACC Cardiovasc Interv. 2017 Apr 24;10(8):774-782. doi: 10.1016/j.jcin.2017.01.022. JACC Cardiovasc Interv. 2017. PMID: 28427593 Free article. Clinical Trial.
Clinical, Angiographic, and Procedural Correlates of Acute, Subacute, and Late Absorb Scaffold Thrombosis.
Ellis SG, Steffenino G, Kereiakes DJ, Stone GW, van Geuns RJ, Abizaid A, Nef H, Cortese B, Testa L, Menichelli M, Tamburino C, Gori T, Kimura T, Serruys PW, Brugaletta S, Sabaté M, Gao RL. Ellis SG, et al. Among authors: kereiakes dj. JACC Cardiovasc Interv. 2017 Sep 25;10(18):1809-1815. doi: 10.1016/j.jcin.2017.06.067. JACC Cardiovasc Interv. 2017. PMID: 28935071 Free article.
Efficacy and Safety of the Absorb Bioresorbable Vascular Scaffold in Females and Males: Results of an Individual Patient-Level Pooled Meta-Analysis of Randomized Controlled Trials.
Shreenivas S, Kereiakes DJ, Ellis SG, Gao R, Kimura T, Onuma Y, Piard-Ruster K, Zhang Y, Koo K, Vu MT, Serruys PW, Stone GW. Shreenivas S, et al. Among authors: kereiakes dj. JACC Cardiovasc Interv. 2017 Sep 25;10(18):1881-1890. doi: 10.1016/j.jcin.2017.07.036. JACC Cardiovasc Interv. 2017. PMID: 28935081 Free article.
579 results